Ethris

Ethris is pioneering the development of next-generation mRNA therapeutics and vaccines using its suite of proprietary and best-in-class mRNA and LNP platforms.

[Ethris @ethris_mRNA]

This #NationalDoctorsDay, we extend our heartfelt thank you to the doctors that share our vision of advancing the development of innovative mRNA-based vaccines and therapies.

[Ethris @ethris_mRNA]

Our Business Development team is attending the #BIOEuropeSpring conference in Barcelona, Spain presented by @EBDGroup! We look forward to connecting with the biopharma community to discuss potential partnerships that will help us advance our pipeline. https://t.co/2U1DCPPyQO

[Ethris @ethris_mRNA]

As we further advance our clinical efforts, we look forward to highlighting the pulmonary delivery capabilities of our lead product candidates. #LearnMore about the unmet medical need within our therapeutic program areas: https://t.co/Cbp8KWPPUY

[Ethris @ethris_mRNA]

Our goal is to develop therapeutics for the treatment of rare diseases such as Primary Ciliary Dyskinesia (PCD) and Pulmonary alveolar proteinosis (PAP). This #RareDiseaseDay and beyond, we’re proud to focus on helping those living with rare diseases we aim to treat.

[Ethris @ethris_mRNA]

#ICYMI, our study of ETH47 has advanced into the clinical phase. ETH47 was developed using Ethris’ Stabilized Non-Immunogenic mRNA (SNIM®RNA) platform. To learn more about our technology, see here: https://t.co/chLKoiD6VI

[Ethris @ethris_mRNA]

The Business of Biotech podcast featuring our CEO, Dr. Carsten Rudolph, is now available! Thank you to host Matthew Pillar for allowing us to expand on our mission. Listen now: https://t.co/zXi4UDYC14

[Ethris @ethris_mRNA]

Our CMO, Dr. Thomas Langenickel, presented a poster on our progress in #PrimaryCiliaryDyskinesia at @PCDFoundation's On the Move International Scientific Conference in Puerto Rico last week. We're honored to be part of advancing treatment for those in the #PCD community. #OTM2024

[Ethris @ethris_mRNA]

Our Chief Technology Officer, Dr. Christian Plank, will be speaking at TIDES Asia in Kyoto, Japan, on March 21 at 8:15. His session will focus on the use of mRNA technology in our lead candidate for preventing and treating viral infections. Learn more: https://t.co/Sj6NmFdKgp

[Ethris @ethris_mRNA]

Our CMO, Dr. Thomas Langenickel, spoke with @GlobalGenes on the power behind our inhaled #mRNA product candidate for Primary Ciliary Dyskinesia (PCD), and how it may help patients breathe easier. Thank you to @dslevine for help telling our story.
Listen: https://t.co/sYCP8ZeAjL

[Ethris @ethris_mRNA]

@dslevine @GlobalGenes Thank you for helping to tell our story!

[Ethris @ethris_mRNA]

#ICYMI, our CEO, Dr. Carsten Rudolph, Estelle Beguin, PhD, and Nigel Horscroft presented at the 3rd Annual #mRNA-Based Therapeutics Summit. Each gave a unique look into our pipeline & research. We look forward to more in 2024! #WorldRNASeries

[Ethris @ethris_mRNA]

Here is a sneak peak of our CEO, Dr. Carsten Rudolph, speaking with Matthew Pillar, host of the Business of Biotech podcast at #JPM2024. Stay tuned for the release of the episode in the coming months, which will discuss our recent developments in mRNA technology and more.

[Ethris @ethris_mRNA]

Our leadership team will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit. Join us January 23-25 in Berlin to learn about our pipeline. Register now: https://t.co/y3eLNUrq3V

[Ethris @ethris_mRNA]

#DYK that our first product candidate to move to clinic, ETH47, is a differentiated approach to potentially treat and prevent severe disease following respiratory viral infections, especially in patients at risk? Read more: https://t.co/8thADZ5dGv

[Ethris @ethris_mRNA]

We're thrilled to announce our participation in the prestigious @JPMorgan Healthcare Conference this year! Meet with us to learn how we’re navigating the future of #mRNA and uncover groundbreaking innovations. #JPM24 #JPM2024

[Ethris @ethris_mRNA]

Our team has been traveling the world in 2023, attending some of the most influential conferences and events in the #biotech industry to discuss our mRNA and LNP technology platforms. We are excited about what's in store for the #NewYear! Learn more: https://t.co/kslqzIzWfK

[Ethris @ethris_mRNA]

Our CEO, Carsten Rudolph, speaks with Advancing RNA on upcoming advancements in #RNA technology. The conversation reveals that there is a lot to look forward to in the #NewYear, including our #ClinicalTrial. Read the feature: https://t.co/jJ5kDdBD37

[Ethris @ethris_mRNA]

From all of us at Ethris, #HappyHolidays! We had a wonderful time celebrating with the team at our holiday party. Thank you all for the support in further developing our pipeline – we couldn’t do it without those who believe in our mission to deliver the future of #RNAMedicine.

[Ethris @ethris_mRNA]

We are thrilled to share a major milestone: The first participant has been dosed in our Phase I #ClinicalTrial for the first-in-class ETH47. We look forward to seeing how this study can fulfill the unmet need in addressing respiratory viral infections. https://t.co/a7ffBRY73t

[Ethris @ethris_mRNA]

Our CEO, Dr. Carsten Rudolph, is featured in this @GoHealio publication about the potential
behind ETH47, an inhaled mRNA-based therapy for respiratory infections. Read the article: https://t.co/jOKdavnMF7